Free the flow

Introducing the world’s first wire-free intraplaque crossing and one-step vessel preparation platform

Discover AtheroplastyTM Innovation 

INTRAPLAQUE ATHEROPLASTY

Three Mechanisms.
One Interface.
Unlimited Potential.

SantrevaTM-ATK Endovascular Revascularization Catheter

Simultaneously combining mechanisms and features designed for intraplaque traversal with axial plaque cutting, lateral plaque compression, and channel formation to revascularize severely or totally occluded arteries, with minimal risk of embolism, flow-limiting dissection, or major perforation in severely stenotic lesions, including CTOs1 – welcome to the new era in endovascular revascularization.

SantrevaTM-ATK Endovascular Revascularization Catheter

Simultaneously combining mechanisms and features designed for intraplaque traversal with axial plaque cutting, lateral plaque compression, and channel formation to revascularize severely or totally occluded arteries, with minimal risk of embolism, flow-limiting dissection, or major perforation in severely stenotic lesions, including CTOs1 – welcome to the new era in endovascular revascularization.

RESTOR-1 Pivotal Trial Key Findings

Revascularization Confirmed.
Simplification Accomplished.

Confirming revascularization in trial results showed strong evidence in support of Atheroplasty.1

90 %
Overall Success
95 %
Successful Cases Were Crossed Antegrade
0
Device-Related MAEs
See the Clinical Evidence
1Banerjee, S. et al.  Am J Cardiol. 2026 Mar 15:263:33-42

From Proximal Cap to True Lumen
Introducing Santreva-ATK Endovascular Revascularization Catheter

Santreva-ATK is an all-in-one, large-profile, manually controlled, and guidewire-free endovascular revascularization solution, with full force range and control to tackle the wide range of plaque morphologies, designed to limit damage to the vessel wall.

This device fundamentally changes how we approach complex peripheral interventions. By simplifying multiple procedural steps into a more intuitive workflow, it allows me to focus on outcomes rather than CTO crossing.

Peter Soukas, MD, FACC, FSCAI, FSVM, FACP

Director of Vascular Medicine and Interventional Vascular Lab at Brown Cardiovascular Institute, Director of Brown Vascular & Endovascular Medicine Fellowship, Associate Professor of Medicine, Warren Alpert School of Medicine at Brown University Rhode Island, USA